SCHEMBL29920871

SCHEMBL29920871

CCc1ccn(C)c1C(N)=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
FGFR4 P22455 1/20 0.33
FGFR3 P22607 1/20 0.33
PARP10 Q53GL7 1/20 0.32
LMNA P02545 1/20 0.32
GABRA1 P14867 1/20 0.31
GABRB2 P47870 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CCNC P24863 1/20 0.31
CDK8 P49336 1/20 0.31
KDM4E B2RXH2 2/20 0.31
MAP2K2 P36507 1/20 0.31
MAP2K1 Q02750 1/20 0.31
KDM6A O15550 1/20 0.31
KDM4A O75164 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25072434 0.75 KDM4E (0.35) MEN1KMT2ACCNCCDK8KDM4E
SCHEMBL1665468 0.75 BRD4 (0.38) MEN1KMT2APARP10SMN1; SMN2CCNC
SCHEMBL31201169 0.73 PKM (0.36) KMT2ALMNASMN1; SMN2CCNCCDK8
SCHEMBL31710685 0.73 AR (0.33) MEN1KMT2APARP10SMN1; SMN2CCNC
SCHEMBL16992853 0.73 MAP2K1 (0.34) PARP10SMN1; SMN2CCNCCDK8KDM4E
SCHEMBL6485082 0.71 SMN1; SMN2 (0.30) SMN1; SMN2CCNCCDK8MAP2K2MAP2K1
SCHEMBL29740453 0.70 MAPK1 (0.46) MEN1KMT2ALMNAKDM4E
SCHEMBL29740450 0.70 MAPK1 (0.46) MEN1KMT2ALMNAKDM4E
SCHEMBL14625802 0.67 CRBN (0.33) GABRA1GABRB2KDM4EKDM6AKDM4A
SCHEMBL13360703 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12351580-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC. (US) 2025-07-08 US disclosed
US-20240067649-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY INC (US) 2024-02-29 US disclosed
US-11827632-B2 NLRP3 modulators INNATE TUMOR IMMUNITY, INC (US) 2023-11-28 US disclosed
US-20220289736-A1 NLRP3 MODULATORS INNATE TUMOR IMMUNITY INC (US) 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827632-B2 NLRP3 modulators NLRP3, NLRP1, NOD1 MEN1 3939/4885KMT2A 4090/4885FGFR1 2119/4885
US-20220289736-A1 NLRP3 MODULATORS NLRP3, NLRP1, NOD1 MEN1 3939/4885KMT2A 4090/4885FGFR1 2119/4885
US-12351580-B2 NLRP3 modulators NLRP3, NLRP1, NOD1 MEN1 3939/4885KMT2A 4090/4885FGFR1 2119/4885
US-20240067649-A1 NLRP3 MODULATORS NLRP3, NLRP1, NOD1 MEN1 3939/4885KMT2A 4090/4885FGFR1 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.